mammaprint dna microarray-based test for prognosis of her2þ early breast cancers (Agendia BV)
90
Structured Review
Agendia BV
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+microarray+testing/mammaprint+dna+microarray+based+test+for+prognosis+of+her2%C3%BE+early+breast+cancers/pm20346697-199-14-13
Average 90 stars, based on 1 article reviews
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+microarray+testing/mammaprint+dna+microarray+based+test+for+prognosis+of+her2%C3%BE+early+breast+cancers/pm20346697-199-14-13
Average 90 stars, based on 1 article reviews
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Microarray:Article Title: Genetic reference materials and their application to haematology. Article Snippet: Genetic investigations are becoming increasingly useful and widespread in many areas of human health.. However, there is a worldwide lack of certified reference materials for use in genetic testing, meaning that tests arebeing runwithoutwellvalidated controls andnewassays aremoredifficult todevelopandvalidate.. We have responded to this challenge by starting a programme of developing genetic reference materials (GRMs) for international accreditation and worldwide distribution. |
